CME : 1
MOC : 1
Hours : 1
Clinical Updates and Expert Guidance in Prostate Cancer is organized by i3 Health and will be held on May 29, 2020.
• i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
In recent years, the therapeutic armamentarium for advanced prostate cancer has expanded rapidly to now include novel hormone therapies, second-generation taxanes, radiopharmaceuticals, immunotherapy, PARP inhibitors, and bone-targeted and bone metastasis-targeted agents. In this virtual symposium, Judd Moul, MD, Duke University School of Medicine, will review emerging data on novel therapies for metastatic castration-sensitive, metastatic castration-resistant, and nonmetastatic castration-resistant disease. Case challenges will be used to illustrate strategies for optimizing treatment in the context of confounding patient and tumor variables. Learners who attend the live virtual symposium will be able to engage in these case studies via audience polling. At the end of the activity, learners will have the opportunity to present questions to Dr. Moul and gain expert perspectives on prostate cancer management.
Statement of Need:
Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.
Upon completion of this activity, participants should be able to:
• Evaluate recent efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant nonmetastatic prostate cancer
• Evaluate emerging efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant metastatic prostate cancer
• Assess recent study findings on novel combination and sequential treatment strategies for prostate cancer and their implications for current practice
Judd W. Moul, MD, Professor of Urologic Surgery, Duke University School of Medicine
Medical oncologists, radiation oncologists, urologists, and other health care professionals involved in the treatment of patients with prostate cancer.
Browse Online CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine